Symbols / IMVT Stock $28.65 -1.41% Immunovant, Inc.

Healthcare • Biotechnology • United States • NMS
IMVT (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Eric Venker M.D., Pharm.D.
Exch · Country NMS · United States
Market Cap 5.83B
Enterprise Value 4.84B
Income -464.20M
Sales —
FCF (ttm) -260.59M
Book/sh 4.85
Cash/sh 4.89
Employees 362
Insider 10d —
IPO Jun 21, 2019
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -11.09
PEG —
P/S —
P/B 5.91
P/C —
EV/EBITDA -9.94
EV/Sales —
Quick Ratio 15.04
Current Ratio 15.74
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -2.67
EPS next Y -2.58
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-20
Earnings (prior) 2026-02-06
ROA -41.33%
ROE -69.35%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 203.53M
Shs Float 77.04M
Insider Own 57.26%
Instit Own 55.52%
Short Float 20.89%
Short Ratio 11.50
Short Interest 18.59M
52W High 30.16
vs 52W High -5.01%
52W Low 13.52
vs 52W Low 111.91%
Beta 0.70
Impl. Vol. 3.13%
Rel Volume 0.83
Avg Volume 1.37M
Volume 1.13M
Target (mean) $40.29
Tgt Median $42.00
Tgt Low $22.00
Tgt High $66.00
# Analysts 17
Recom Buy
Prev Close $29.06
Price $28.65
Change -1.41%
About

Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$40.29
Mean price target
2. Current target
$28.65
Latest analyst target
3. DCF / Fair value
$-23.05
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$28.65
Low
$22.00
High
$66.00
Mean
$40.29

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-15 main Goldman Sachs Neutral → Neutral $32
2026-02-10 reit HC Wainwright & Co. Buy → Buy $35
2026-02-09 main Guggenheim Buy → Buy $44
2026-01-08 main Truist Securities Hold → Hold $22
2026-01-06 up Wolfe Research Peer Perform → Outperform $50
2025-12-15 main Goldman Sachs Neutral → Neutral $28
2025-10-14 init Truist Securities — → Hold $16
2025-09-30 main JP Morgan Overweight → Overweight $33
2025-09-04 reit HC Wainwright & Co. Buy → Buy $35
2025-08-12 main JP Morgan Overweight → Overweight $37
2025-08-12 main B of A Securities Buy → Buy $30
2025-07-28 main UBS Neutral → Neutral $18
2025-04-22 down UBS Buy → Neutral $17
2025-03-20 reit Guggenheim Buy → Buy —
2025-03-20 main B of A Securities Buy → Buy $33
2025-03-19 reit HC Wainwright & Co. Buy → Buy $51
2025-03-10 reit Guggenheim Buy → Buy —
2025-02-10 main Guggenheim Buy → Buy $44
2025-02-10 reit HC Wainwright & Co. Buy → Buy $51
2025-02-07 reit HC Wainwright & Co. Buy → Buy $51
News
RSS: Latest IMVT news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-01 SUSMAN ROBERT GRAHAM Director — 2,502 $27.17 $67,979
2026-04-23 GIRÃO TIAGO M Chief Financial Officer — 25,760 $29.62 $763,011
2026-04-23 STOUT JAY S Chief Technology Officer — 2,754 $29.62 $81,573
2026-04-08 STOUT JAY S Chief Technology Officer — 10,132 $24.83 $251,578
2026-04-08 GLORIA MELANIE Chief Operating Officer — 8,722 $24.83 $216,567
2026-04-08 VAN TUYL CHRISTOPHER Officer — 5,165 $24.83 $128,247
2026-04-07 FROMKIN ANDREW J Director — 13,880 $0.00 $0
2026-04-07 GIRÃO TIAGO M Chief Financial Officer — 64,968 $0.00 $0
2026-04-07 PANDE ATUL Director — 13,880 $0.00 $0
2026-04-07 BAUER JAKE Director — 13,880 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
438.15
+62.15%
270.21
+29.74%
208.28
+33.48%
156.03
Research And Development
360.92
+69.50%
212.93
+32.87%
160.26
+57.41%
101.81
Selling General And Administration
77.23
+34.84%
57.28
+19.29%
48.02
-11.44%
54.23
General And Administrative Expense
77.23
+34.84%
57.28
+19.29%
48.02
-11.44%
54.23
Other Gand A
77.23
+34.84%
57.28
+19.29%
48.02
-11.44%
54.23
Total Expenses
438.15
+62.15%
270.21
+29.74%
208.28
+33.48%
156.03
Operating Income
-438.15
-62.15%
-270.21
-29.74%
-208.28
-33.48%
-156.03
EBITDA
-437.77
-62.15%
-269.98
-29.75%
-208.08
-33.47%
-155.91
Normalized EBITDA
-437.77
-70.02%
-257.48
-29.98%
-198.08
-27.05%
-155.91
Reconciled Depreciation
0.38
+63.20%
0.23
+19.69%
0.19
+53.17%
0.13
EBIT
-438.15
-62.15%
-270.21
-29.74%
-208.28
-33.48%
-156.03
Total Unusual Items
0.00
+100.00%
-12.50
-25.00%
-10.00
0.00
Total Unusual Items Excluding Goodwill
0.00
+100.00%
-12.50
-25.00%
-10.00
0.00
Special Income Charges
0.00
+100.00%
-12.50
-25.00%
-10.00
0.00
Other Special Charges
—
12.50
+25.00%
10.00
—
Restructuring And Mergern Acquisition
0.00
-100.00%
12.50
+25.00%
10.00
0.00
Net Income
-413.84
-59.58%
-259.34
-22.93%
-210.96
-34.60%
-156.73
Pretax Income
-412.95
-59.58%
-258.77
-22.67%
-210.95
-34.52%
-156.81
Net Non Operating Interest Income Expense
24.73
-0.87%
24.95
+229.22%
7.58
0.00
Net Interest Income
24.73
-0.87%
24.95
+229.22%
7.58
0.00
Interest Income Non Operating
24.73
-0.87%
24.95
+229.22%
7.58
0.00
Interest Income
24.73
-0.87%
24.95
+229.22%
7.58
0.00
Other Income Expense
0.47
+103.49%
-13.51
-31.75%
-10.25
-1212.80%
-0.78
Other Non Operating Income Expenses
0.47
+146.73%
-1.01
-298.42%
-0.25
+67.61%
-0.78
Tax Provision
0.89
+57.14%
0.57
+6200.00%
0.01
+110.71%
-0.08
Tax Rate For Calcs
0.00
+0.00%
0.00
0.00
-100.00%
0.00
Tax Effect Of Unusual Items
0.00
+100.00%
-2.62
0.00
0.00
Net Income Including Noncontrolling Interests
-413.84
-59.58%
-259.34
-22.93%
-210.96
-34.60%
-156.73
Net Income From Continuing Operation Net Minority Interest
-413.84
-59.58%
-259.34
-22.93%
-210.96
-34.60%
-156.73
Net Income From Continuing And Discontinued Operation
-413.84
-59.58%
-259.34
-22.93%
-210.96
-34.60%
-156.73
Net Income Continuous Operations
-413.84
-59.58%
-259.34
-22.93%
-210.96
-34.60%
-156.73
Normalized Income
-413.84
-65.89%
-249.46
-24.13%
-200.96
-28.22%
-156.73
Net Income Common Stockholders
-413.84
-59.58%
-259.34
-22.93%
-210.96
-34.60%
-156.73
Diluted EPS
-2.73
-45.21%
-1.88
-9.94%
-1.71
-19.58%
-1.43
Basic EPS
-2.73
-45.21%
-1.88
-9.94%
-1.71
-19.58%
-1.43
Basic Average Shares
151.57
+9.76%
138.10
+12.21%
123.08
+12.21%
109.68
Diluted Average Shares
151.57
+9.76%
138.10
+12.21%
123.08
+12.21%
109.68
Diluted NI Availto Com Stockholders
-413.84
-59.58%
-259.34
-22.93%
-210.96
-34.60%
-156.73
Line Item Trend 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total Assets
776.22
+16.49%
666.37
+64.19%
405.84
-21.28%
515.56
Current Assets
767.66
+15.30%
665.77
+64.66%
404.33
-21.17%
512.93
Cash Cash Equivalents And Short Term Investments
713.97
+12.37%
635.37
+68.74%
376.53
-23.75%
493.82
Cash And Cash Equivalents
713.97
+12.37%
635.37
+68.74%
376.53
-23.75%
493.82
Cash Financial
—
—
—
493.82
Receivables
2.51
-54.37%
5.50
+521.81%
0.89
-93.12%
12.86
Accounts Receivable
2.08
-60.95%
5.34
+662.43%
0.70
-94.28%
12.23
Taxes Receivable
0.43
+157.23%
0.17
-10.27%
0.18
-70.73%
0.63
Prepaid Assets
—
—
—
6.25
Other Current Assets
51.18
+105.53%
24.90
-7.48%
26.92
+330.45%
6.25
Total Non Current Assets
8.56
+1338.66%
0.59
-60.47%
1.50
-42.84%
2.63
Net PPE
0.94
+58.32%
0.59
-60.47%
1.50
-42.84%
2.63
Gross PPE
0.94
+58.32%
0.59
-60.47%
1.50
-42.84%
2.63
Other Properties
0.94
+58.32%
0.59
-60.47%
1.50
-42.84%
2.63
Other Non Current Assets
7.62
—
—
—
Total Liabilities Net Minority Interest
68.78
+41.49%
48.61
+12.14%
43.34
-5.24%
45.74
Current Liabilities
68.78
+41.49%
48.61
+12.27%
43.30
-2.75%
44.52
Payables And Accrued Expenses
53.06
+57.32%
33.73
-2.51%
34.59
-11.11%
38.92
Payables
17.93
+150.06%
7.17
+321.02%
1.70
-90.94%
18.80
Accounts Payable
17.66
+146.76%
7.16
+428.82%
1.35
-92.74%
18.63
Current Accrued Expenses
35.13
+32.29%
26.56
-19.26%
32.89
+63.48%
20.12
Pensionand Other Post Retirement Benefit Plans Current
15.62
+5.93%
14.74
+95.80%
7.53
+68.99%
4.46
Current Debt And Capital Lease Obligation
0.10
-28.99%
0.14
-88.24%
1.17
+2.45%
1.15
Current Capital Lease Obligation
0.10
-28.99%
0.14
-88.24%
1.17
+2.45%
1.15
Total Non Current Liabilities Net Minority Interest
0.00
0.00
-100.00%
0.05
-96.14%
1.22
Long Term Debt And Capital Lease Obligation
—
0.00
-100.00%
0.05
-96.14%
1.22
Long Term Capital Lease Obligation
—
0.00
-100.00%
0.05
-96.14%
1.22
Stockholders Equity
707.45
+14.52%
617.76
+70.42%
362.49
-22.84%
469.82
Common Stock Equity
707.45
+14.52%
617.76
+70.42%
362.49
-22.84%
469.82
Capital Stock
0.02
+14.29%
0.01
+7.69%
0.01
+8.33%
0.01
Common Stock
0.02
+14.29%
0.01
+7.69%
0.01
+8.33%
0.01
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
170.11
+16.85%
145.58
+11.70%
130.33
+11.89%
116.48
Ordinary Shares Number
170.11
+16.85%
145.58
+11.70%
130.33
+11.89%
116.48
Additional Paid In Capital
1,945.49
+34.96%
1,441.52
+55.34%
927.98
+12.51%
824.80
Retained Earnings
-1,239.52
-50.12%
-825.68
-45.79%
-566.35
-59.36%
-355.39
Gains Losses Not Affecting Retained Earnings
1.46
-23.53%
1.91
+123.94%
0.85
+110.89%
0.40
Other Equity Adjustments
1.46
-23.53%
1.91
+123.94%
0.85
+110.89%
0.40
Total Equity Gross Minority Interest
707.45
+14.52%
617.76
+70.42%
362.49
-22.84%
469.82
Total Capitalization
707.45
+14.52%
617.76
+70.42%
362.49
-22.84%
469.82
Working Capital
698.89
+13.24%
617.16
+70.94%
361.04
-22.92%
468.41
Invested Capital
707.45
+14.52%
617.76
+70.42%
362.49
-22.84%
469.82
Total Debt
0.10
-28.99%
0.14
-88.69%
1.22
-48.39%
2.36
Capital Lease Obligations
0.10
-28.99%
0.14
-88.69%
1.22
-48.39%
2.36
Net Tangible Assets
707.45
+14.52%
617.76
+70.42%
362.49
-22.84%
469.82
Tangible Book Value
707.45
+14.52%
617.76
+70.42%
362.49
-22.84%
469.82
Dueto Related Parties Current
0.27
+1720.00%
0.01
-95.71%
0.35
+104.68%
0.17
Preferred Shares Number
0.01
+0.00%
0.01
+0.00%
0.01
+0.00%
0.01
Line Item Trend 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Operating Cash Flow
-375.87
-75.46%
-214.23
-13.83%
-188.19
-77.35%
-106.11
Cash Flow From Continuing Operating Activities
-375.87
-75.46%
-214.23
-13.83%
-188.19
-77.35%
-106.11
Net Income From Continuing Operations
-413.84
-59.58%
-259.34
-22.93%
-210.96
-34.60%
-156.73
Depreciation Amortization Depletion
0.38
+63.20%
0.23
+19.69%
0.19
+53.17%
0.13
Depreciation
0.38
+63.20%
0.23
+19.69%
0.19
+53.17%
0.13
Depreciation And Amortization
0.38
+63.20%
0.23
+19.69%
0.19
+53.17%
0.13
Other Non Cash Items
0.13
-88.23%
1.13
-0.09%
1.13
+2.26%
1.11
Stock Based Compensation
49.49
+20.36%
41.12
+27.31%
32.30
-5.69%
34.24
Change In Working Capital
-12.03
-557.10%
2.63
+124.25%
-10.85
-171.67%
15.14
Change In Receivables
2.97
+165.18%
-4.56
-137.28%
12.22
+204.33%
-11.72
Changes In Account Receivables
3.23
+170.61%
-4.58
-138.91%
11.76
+201.13%
-11.63
Change In Prepaid Assets
-26.99
-1832.35%
1.56
+107.59%
-20.53
-1060.83%
2.14
Change In Payables And Accrued Expense
19.86
+191.92%
6.80
+586.00%
-1.40
-105.40%
25.90
Change In Accrued Expense
8.92
+561.45%
1.35
-91.33%
15.57
+64.36%
9.47
Change In Payable
10.94
+100.53%
5.46
+132.15%
-16.97
-203.27%
16.43
Change In Account Payable
10.68
+84.72%
5.78
+133.78%
-17.12
-205.35%
16.25
Change In Other Current Assets
-7.74
0.00
0.00
—
Change In Other Current Liabilities
-0.14
+88.23%
-1.17
-2.36%
-1.15
+2.88%
-1.18
Investing Cash Flow
-0.76
-110.83%
-0.36
-82.74%
-0.20
+22.44%
-0.25
Cash Flow From Continuing Investing Activities
-0.76
-110.83%
-0.36
-82.74%
-0.20
+22.44%
-0.25
Net PPE Purchase And Sale
-0.76
-110.83%
-0.36
-82.74%
-0.20
+22.44%
-0.25
Purchase Of PPE
-0.76
-110.83%
-0.36
-82.74%
-0.20
+22.44%
-0.25
Capital Expenditure
-0.76
-110.83%
-0.36
-82.74%
-0.20
+22.44%
-0.25
Financing Cash Flow
454.49
-3.80%
472.43
+566.47%
70.89
-64.58%
200.13
Cash Flow From Continuing Financing Activities
454.49
-3.80%
472.43
+566.47%
70.89
-64.58%
200.13
Net Issuance Payments Of Debt
—
—
—
0.00
Repayment Of Debt
—
—
—
0.00
Long Term Debt Payments
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
450.00
-4.81%
472.75
+570.56%
70.50
0.00
Proceeds From Stock Option Exercised
4.81
-15.51%
5.69
+766.67%
0.66
0.00
Net Other Financing Charges
-0.32
+94.69%
-6.01
-2110.29%
-0.27
-100.14%
200.13
Changes In Cash
77.86
-69.80%
257.84
+319.43%
-117.50
-225.32%
93.76
Effect Of Exchange Rate Changes
0.75
-24.77%
0.99
+351.36%
0.22
+339.13%
-0.09
Beginning Cash Position
635.37
+68.74%
376.53
-23.75%
493.82
+23.41%
400.15
End Cash Position
713.97
+12.37%
635.37
+68.74%
376.53
-23.75%
493.82
Free Cash Flow
-376.63
-75.52%
-214.59
-13.91%
-188.39
-77.11%
-106.37
Income Tax Paid Supplemental Data
1.20
+136.15%
0.51
0.00
0.00
Common Stock Issuance
450.00
-4.81%
472.75
+570.56%
70.50
0.00
Issuance Of Capital Stock
450.00
-4.81%
472.75
+570.56%
70.50
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category